Physician profile
Roy Small
NPI 1235106410
$1,039.98
in general payments reported to CMS, 2019-2025
11 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2022: $15.29 · 2023: $390 · 2024: $139 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $275.00 | 2023-2025 | Amvuttra |
| Akcea Therapeutics, INC. | $258.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $146.28 | 2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $124.99 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2023 | Lifevest |
| Abbott Laboratories | $55.76 | 2023-2025 | Triclip, Cardiomems |
| Impulse Dynamics (USA) INC. | $34.27 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.25 | 2025 | Farxiga |
| Livanova USA, INC. | $15.29 | 2022 | |
| Pfizer INC. | $13.53 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.